Семейный анализ генетической предрасположенности к рассеянному склерозу

Список литературы

1. Гусев Е.И. Рассеянный склероз и другие демиелинизирующие заболевания. // Миклош. 2004.-540 с.
2. Richards R.G., Sampson F.C., Beard S.M., Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess, 2002, Y.6 № 10, P.1−73.
3. Dyment D.A., Ebers G.C., Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol, 2004, V.3 № 2, P. 104−10.
4. Zhang H., Zhao H., Merikangas K. Strategies to identify genes for complex diseases. Ann Med, 1997, V.29 № 6, P.493−8.
5. Hattersley А.T., McCarthy M.I. What makes a good genetic association study? Lancet, 2005, V.366 № 9493, P. 1315−23.
6. Risch N.J. Searching for genetic determinants in the new millennium. Nature, 2000, V.405 № 6788, P.847−56.
7. Thomson G. Mapping disease genes: family-based association studies. Am J Hum Genet, 1995, V.57 № 2, P.487−98.
8. Spielman R.S., Ewens W.J. The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet, 1996, V.59 № 5, P.983−9.
9. Terwilliger J.D. A powerful likelihood method for the analysis of linkage disequilibrium between trait loci and one or more polymorphic marker loci. Am J Hum Genet, 1995, V.56 № 3, P.777−87.
10. Spielman R.S., McGinnis R.E. Ewens W.J. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet, 1993, V.52 № 3, P.506−16.
11. Alizadeh M., Genin E., Babron M.C., Birebent B., Cournu-Rebeix I., Yaouanq J., Dreano S., Sawcer S., Compston A., Clanet M., Edan G., Fontaine B., Clerget-Darpoux F.,
12. Semana G. Genetic analysis of multiple sclerosis in Europeans: French data. J Neuroimmunol, 2003, V.143№l-2, P.74−8.
13. Wilier C.J., Dyment D.A., Cherny S., Ramagopalan S.V., Herrera B.M., Morrison K.M., Sadovnick A.D., Risch N.J., Ebers G.C. A genome-wide scan in forty large pedigrees with multiple sclerosis. J Hum Genet, 2007, Y.52 № 12, P.955−62.
14. Макдональд В.Я., Фазекас Ф., Томпсон А. Д. Диагностика рассеянного склероза. Журнал неврологии и психиатрии имени С. С. Корсакова, 2003, Том 2, стр.4−9.
15. Poser С.М., Brinar V.V. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg, 2001, V.103 №l, P. l-11.
16. McDonald W.I., Ron M.A. Multiple sclerosis: the disease and its manifestations. Philos Trans RSocLond В Biol Sci, 1999, V.354№ 1390, P.1615−22.
17. Schmidt H., Williamson D., Ashley-Koch A. HLA-DR15 Haplotype and Multiple Sclerosis: A HuGE Review. Am J Epidemiol, 2007, V.165 № 10, P.1097−109.
18. Kurtzke J.F. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol Sci, 2000, V.21 № 6, P.383−403.
19. Гусев Е.И., Демина Т. Л., Бойко A.H. Рассеянный склероз. // М., 1997. 464с.
20. Dean G. Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. Br Med J, 1967, V.2 N'5554, P.724−30.
21. Farrall M. Mapping genetic susceptibility to multiple sclerosis. Lancet, 1996, V.348 № 9043, P. l674−5.
22. Sadovnick A.D., Ebers G.C., Dyment D.A., Risch N.J. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet, 1996, V.347 N•9017, P. 1728−30.
23. Robertson N.P., Fraser M., Deans J., Clayton D., Walker N., Compston D.A. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain, 1996, V.119 (Pt 2), P.449−55.
24. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun, 2009, V.33№l, P.3−11.
25. Ebers G.C., Sadovnick A.D., Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature, 1995, V.377 N"6545, P.150−1.
26. Sadovnick A.D., Dircks A., Ebers G.C. Genetic counselling in multiple sclerosis: risks to sibs and children of affected individuals. Clin Genet, 1999, V.56 № 2, P. 118−22.
27. Бойко A.H., Фаворова O.O. Рассеянный склероз: молекулярные и клеточные ' механизмы. Молекулярная биология, 1995, Том 29 № 4, стр.727−749.
28. Compston A., Coles A. Multiple sclerosis. Lancet, 2002, V.359 № 9313, Р.1221−31.
29. Bruck W., Stadelmann С. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol, 2005, V.18№ 3, P.221−4.
30. Byrnes A.A., McArthur J.C., Karp C.L. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol, 2002, V.51 № 2, P.165−74.
31. Prat A., Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol, 2005, V.18 N'3, P.225−30.
32. Bach J.F. Infections and autoimmune diseases. J Autoimmun, 2005, V.25 Suppl., P.74−80.
33. Bar-Or A., Oliveira E.M., Anderson D.E., Hafler D.A. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol, 1999, V.100№l-2, P.252−9.
34. Hauser S.L., Oksenberg J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron, 2006, V.52 №l, P.61−76.
35. Kikly K., Liu L., Na S., Sedgwick J.D. The IL-23/Th (17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol, 2006, V.18 №б, P.670−5.
36. Romagnani S. Regulation of the T cell response. Clin Exp Allergy, 2006, V.36 № 11, P.1357−66.
37. Заргарова T.A., Фаворова O.O. Исследование роли цитокинов при экспериментальном аутоиммунном энцефаломиелите и рассеянном склерозе. Иммунология, 1999, Том 5, стр.9−13.
38. Compston A., Sadovnick A.D. Epidemiology and genetics of multiple sclerosis. Curr Opin Neurol Neurosurg, 1992, V.5 № 2, P. l75−81.
39. Bomprezzi R., Kovanen P.E., Martin R. New approaches to investigating heterogeneity in complex traits. J Med Genet, 2003, V.40 N'8, P.553−9.
40. Oksenberg J.R., Baranzini S.E., Sawcer S., Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet, 2008, V.9 № 7, P.516−26.
41. Herrera B.M., Ebers G.C. Progress in deciphering the genetics of multiple sclerosis. Curr Opin Neurol, 2003, Y.16 № 3, P.253−8.
42. Судомоина M.A., Фаворова O.O. Поиск генов предрасположенности к рассеянному склерозу. Молекулярная биология, 2000, Том 34 № 4, стр.654−70.
43. Фаворова O.O., Кулакова О. Г., Бойко A.H. Рассеянный склероз как полигенное заболевание: современное состояние проблемы. Генетика, 2010, Том.46 № 3, стр.302−313.
44. Abdeen H., Heggarty S., Hawkins S.A., Hutchinson M., McDonnell G.V., Graham C.A. Mapping candidate non-MHC susceptibility regions to multiple sclerosis. Genes Immun, 2006, V.7 № 6, P.494−502.
45. Yousefipour G., Erfani N., Momtahan M., Moghaddasi H., Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand, 2009, V.120 № 6, P.424−9.
46. Ban M., Stewart G.J., Bennetts B.H., Heard R., Simmons R., Maranian M., Compston A., Sawcer S.J. A genome screen for linkage in Australian sibling-pairs with multiple sclerosis. Genes Immun, 2002, V.3№ 8, P.464−9.
47. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet, 2009, V.41 № 7, P.824−8.
48. Nada M.A., Labib D.A. Tumor Necrosis Factor Alpha Gene -376 Polymorphism and Susceptibility to Multiple Sclerosis: An Egyptian Study. J Neuroimmune Pharmacol, 2011, V.6 № 142−7.
49. Ronaghi M., Vallian S., Etemadifar M. CD24 gene polymorphism is associated with the disease progression and susceptibility to multiple sclerosis in the Iranian population. Psychiatry Res, 2009, V.170 № 2−3, P.271−2.
50. Coraddu F., Sawcer S., D’Alfonso S., Lai M., Hensiek A., Solla E., Broadley S., Mancosu C., Pugliatti M., Marrosu M.G., Compston A. A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet, 2001, Y.9 № 8, P.621−6.
51. Mirowska-Guzel D., Gromadzka G., Czlonkowski A., Czlonkowska A. Association of
52. MMP1, MMP3, MMP9, and MMP12, polymorphisms with risk and clinical course ofimultiple sclerosis in a Polish population. J Neuroimmunol, 2009, V.214 № 1−2, P. l 13−7.
53. Zivkovic M., Djuric T., Dincic E., Raicevic R., Alavantic D., Stankovic A. Matrix metalloproteinase-9 -1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. J Neuroimmunol, 2007, V.189№l-2, P.147−50.
54. Benesova Y., Vasku A., Stourac P., Hladikova M., Beranek M., Kadanka Z., Novotna H., Bednarik J. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol, 2008, V.205 № 1−2, P.105−9.
55. Olsson T., Hillert J. The genetics of multiple sclerosis and its experimental models. Curr OpinNeurol, 2008, V.2l№ 3, P.255−60.
56. Falk C.T., Rubinstein P. Haplotype relative risks: an easy reliable way to construct a proper control sample for risk calculations. Ann Hum Genet, 1987, V.51 №Pt 3, P.227−33.
57. Noble J.A., Valdes A.M., Bugawan T.L., Apple R.J., Thomson G., Erlich H.A. The HLA class IA locus affects susceptibility to type 1 diabetes. Hum Immunol, 2002, Y.63 № 8, P.657−64.
58. Bilbao J.R., Martin-Pagola A., Calvo B., Perez de Nanclares G., Gepv N., Castano L. Contribution of MIC-A polymorphism to type 1 diabetes mellitus in Basques. Ann N Y Acad Sci, 2002, V.958, P.321−4.
59. Maalej A., Petit-Teixeira E., Michou L., Rebai A., Cornelis F., Ayadi H. Association study of VDR gene with rheumatoid arthritis in the French population. Genes Immun, 2005, V.6 № 8, P.707−11.
60. Schulze T.G., McMahon F.J. Genetic association mapping at the crossroads: which test and why? Overview and practical guidelines. Am J Med Genet, 2002, V.114 №l, P. l-11.
61. Sebro R., Rogus J.J. The power of the Transmission Disequilibrium Test in the presence of population stratification. Eur J Hum Genet, V.18 № 9, P.1032−8.
62. Галимова, В. Л. Ахметова, Э. К. Хуснутдинова. Молекулярпо-генетические основы предрасположенности к псориазу. Генетика., 2008, Том .44 N'5, стр.594−605.
63. Orton S.M., Ramagopalan S.V., Para А.Е., Lincoln M.R., Handunnetthi L., Chao M.J., Morahan J., Morrison K.M., Sadovnick A.D., Ebers G.C. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci, V.305 № 1−2, P. 116−20.
64. Cocco E., Murru M.R., Melis C., Schirru L., Solla E., Lai M., Rolesu M., Marrosu M.G.
65. PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in
66. Sardinian patients. J Neurol, 2004, V.251 № 9, P.1085−8.
67. Cocco E., Mancosu C., Fadda E., Murru M.R., Costa G., Murru R., Marrosu M.G. Lack of evidence for a role of the myelin basic protein gene in multiple sclerosis susceptibility in Sardinian patients. J Neurol, 2002, V.249 №l 1, P. l 552−5.
68. He В., Giedraitis V., Ligers A., Binzer M., Andersen P.M., Forsgren L., Sandkuijl L.A., Hillert J. Sharing of a conserved haplotype suggests a susceptibility gene for multiple sclerosis at chromosome 17pll. Eur J Hum Genet, 2002, V.10 № 4, P.271−5.
69. Martinez Doncel A., Rubio A., Arroyo R., de las Heras V., Martin C., Fernandez-Arquero M., de la Concha E.G. Interleukin-10 polymorphisms in Spanish multiple sclerosis patients. J Neuroimmunol, 2002, Y.131 № 1−2, P.168−72.
70. Dyment D.A., Steckley J.L., Wilier C.J., Armstrong H., Sadovnick A.D., Risch N., Ebers G.C. No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study. J Neuroimmunol, 2002, V.123N'l-2, P.193−8.
71. Curtis D., Sham P.C. A note on the application of the transmission disequilibrium test when a parent is missing. Am J Hum Genet, 1995, V.56 N'3, P. 811−2.
72. Bickeboller H., Margaritte-Jeannin P., Babron M.C., Clerget-Darpoux F. Systematic search of susceptibility loci with methods using gametic disequilibrium. Genet Epidemiol, 1995, V.12N-6, P.577−82.
73. Rice J.P., Neuman R.J., Hoshaw S.L., Daw E.W., Gu C. TDT with covariates and genomic screens with mod scores: their behavior on simulated data. Genet Epidemiol, 1995, V.12N-6, P.659−64.
74. Sham P.C., Curtis D. An extended transmission/disequilibrium test (TDT) for multi-allele marker loci. Ann Hum Genet, 1995, V.59 №Pt 3, P.323−36.
75. Cleves M.A., Olson J.M., Jacobs K.B. Exact transmission-disequilibrium tests with multiallelic markers. Genet Epidemiol, 1997, V.14 № 4, P.337−47.
76. Wilson S.R. On extending the transmission/disequilibrium test (TDT). Ann Hum Genet, 1997, V.61 N’Pt 2, P.151−61.
77. Zhao H., Zhang S., Merikangas K.R., Trixler M., Wildenauer D.B., Sun F., Kidd K.K. Transmission/disequilibrium tests using multiple tightly linked markers. Am J Hum Genet, 2000, V.67N-4, P.936−46.
78. Lazzeroni L.C., Lange K. A conditional inference framework for extending the transmission/disequilibrium test Hum Hered, 1998, V.48N'2, P.67−81.
79. Curtis D. Use of siblings as controls in case-control association studies. Ann Hum Genet, 1997, V.61 №Pt4, P.319−33.
80. Spielman R.S., Ewens W.J. A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. Am J Hum Genet, 1998, V.62 № 2, P.450−8.
81. Hassan A., Sham P.C., Markus H.S. Planning genetic studies in human stroke: sample size estimates based on family history data. Neurology, 2002, Y.58 № 10, P. 1483−8.
82. He X., Zhu D.L., Chu S.L., Jin L., Xiong M.M., Wang G.L., Zhang W.Z., Zhou H.F., Mao S.Y., Zhan Y.M., Zhuang Q.N., Liu X.M., Zhao Y., Huang W. alpha-Adducin gene and essential hypertension in China. Clin Exp Hypertens, 2001, V.23 № 7, P.579−89.
83. Chistiakov D.A., Savost’anov K.V., Nosikov V.V. CTLA4 gene polymorphisms are associated with, and linked to, insulin-dependent diabetes mellitus in a Russian population. BMC Genet, 2001, V.2, P.6.
84. Horvath S., Laird N.M. A discordant-sibship test for disequilibrium and linkage: no need for parental data. Am J Hum Genet, 1998, Y.63 № 6, P.1886−97.
85. Whittaker J.C., Lewis C.M. Power comparisons of the transmission/disequilibrium test and sib-transmission/disequilibrium-test statistics. Am J Hum Genet, 1999, Y.65 № 2, P.578−80.
86. Boehnke M., Langefeld C.D. Genetic association mapping based on discordant sib pairs: the discordant-alleles test. Am J Hum Genet, 1998, V.62 № 4, P.950−61.
87. Sun F., Flanders W.D., Yang Q., Khoury M.J. Transmission disequilibrium test (TDT) when only one parent is available: the 1-TDT. Am J Epidemiol, 1999, V.150 №l, P.97−104.
88. Sun F., Cheng R., Flanders W.D., Yang Q., Khoury M.J. Whole genome association studies for genes affecting alcohol dependence. Genet Epidemiol, 1999, V.17 Suppl 1, P. S337−42.
89. De Marco P., Merello E., Calevo M.G., Mascelli S., Raso A., Cama A., Capra V. Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958G>A polymorphism for neural tube defect risk J Hum Genet, 2006, V.51 № 2, P.98−103.
90. Chen J.H., Cheng K.F. A robust TDT-type association test under informative parental missingness. Stat Med, 2011, V.30 N'3, P.291−7.
91. Belonogova N.M., Axenovich T.I., Aulchenko Y.S., A powerful genome-wide feasible approach to detect parent-of origin effects in studies of quantitative traits. Eur J Hum Genet, 2010, V.18 N'3, P.379−84.
92. Knapp M. The transmission/disequilibrium test and parental-genotype reconstruction: the reconstruction-combined transmission/ disequilibrium test. Am J Hum Genet, 1999, Y.64 № 3, P.861−70.
93. Knapp M. Using exact P values to compare the power between the reconstruction-combined transmission/disequilibrium test and the sib transmission/disequilibrium test. Am J Hum Genet, 1999, V.65N'4, P. 1208−10.
94. Spielman R.S., Ewens W.J. TDT clarification Am J Hum Genet, 1999, V.64 № 2, P.668.
95. Ho G.Y., Bailey-Wilson J.E. The transmission/disequilibrium test for linkage on the X chromosome. Am J Hum Genet, 2000, V.66 № 3, P. 1158−60.
96. Horvath S., Laird N.M., Knapp M. The transmission/disequilibrium test and parental-genotype reconstruction for X-chromosomal markers. Am J Hum Genet, 2000, V.66 N'3, P. l 161−7.
97. Martin E.R., Monks S.A., Warren L.L., Kaplan N.L. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am J Hum Genet, 2000, V.67 № 1, P.146−54.
98. Allison D.B. Transmission-disequilibrium tests for quantitative traits. Am J Hum Genet, 1997, V.60 N'3, P.676−90.
99. Rabinowitz D. A transmission disequilibrium test for quantitative trait loci. Hum Hered, 1997, V.47 N'6, P.342−50.
100. Xiong M.M., Krushkal J., Boerwinkle E. TDT statistics for mapping, quantitative trait loci. Ann Hum Genet, 1998, V.62 N’Pt 5, P.431−52.
101. George Y., Tiwari H.K., Zhu X., Elston R.C. A test of transmission/disequilibrium for quantitative traits in pedigree data, by multiple regression. Am J Hum Genet, 1999, s1. V.65N-1, P.236−45.
102. Waldman I.D., Robinson B.F., Rowe D.C. A logistic regression based extension of the TDT for continuous and categorical traits. Ann Hum Genet, 1999, V.63 N’Pt 4, P.329−40.
103. Lunetta K.L., Faraone S.V., Biederman J., Laird N.M. Family-based tests of association and linkage that use unaffected sibs, covariates, and interactions. Am J Hum Genet, 2000, V.66№ 2, P.605−14.
104. Sun F.Z., Flanders W.D., Yang Q.H., Zhao H.Y. Transmission/disequilibrium tests for quantitative traits. Ann Hum Genet, 2000, V.64 N’Pt 6, P.555−65.
105. Zhang L., Bonham A.J., Li J., Pei Y.F., Chen J., Papasian C.J., Deng H.W. Family-based bivariate association tests for quantitative traits. PLoS One, 2009, V.4 № 12, P. e8133.
106. Laird N.M., Horvath S., Xu X. Implementing a unified approach to family-based tests of association. Genet Epidemiol, 2000, Y.19 Suppl 1, P. S36−42.
107. Rabinowitz D., Laird N. A unified approach to adjusting association tests for population admixture with arbitrary pedigree structure and arbitrary missing marker information. Hum Hered, 2000, V.50N-4, P.211−23.
108. J. Sambrook, E. F. Fritsch, T. Maniatis: Molecular Cloning, ed Nolan, C. Cold Spring Harbor Press, 1989, 9.17−9.19.
109. Pravica V., Asderakis A., Perrey C., Hajeer A., Sinnott P.J., Hutchinson I.V. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet, 1999, Y.26 №l, P. 1−3.
110. He B., Navikas V., Lundahl J, Soderstrom M., Hillert J. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol, 1995, V.63 № 2, P.143−7.
111. Sandford A.J., Pare P.D. Direct PCR of small genomic DNA fragments from serum. Biotechniques, 1997, V.23№ 5, P.890−2.
112. Purcell S., Sham P., Daly M.J. Parental phenotypes in family-based association analysis. Am J Hum Genet, 2005, V.76N-2, P.249−59.
113. Kwon О.J., Kami A., Israel S., Brautbar С., Amar A., Meiner Z., Abramsky O., Karussis D. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol, 1999, V.56N-5, P.555−60.
114. Coraddu F., Reyes-Yanez M.P., Parra A., Gray J., Smith S.I., Taylor C.J., Compston D.A. HLA associations with multiple sclerosis in the Canary Islands. J Neuroimmunol, 1998, V.87 N"1−2, P. 130−5.
115. Ramagopalan S.V., Ebers G.C. Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Med, 2009, V. l N’l 1, P.105.
116. Prud’homme G.J., Piccirillo C.A. The inhibitory effects of transforming growth factor-beta-1 (TGF-betal) in autoimmune diseases. J Autoimmun, 2000, V.14 N’l, P.23−42.
117. Chen W., Jin W., Wahl S.M. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) Tcells. J Exp Med, 1998, V.188N-10, P.1849−57.
118. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci, 1996, V.19 N'8, P.312−8.
119. Dore-Duffy P., Washington R., Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol, 1993, V.331, P.243−8.
120. Frigerio S., Gelati M., Ciusani E., Corsini E., Dufour A., Massa G., Salmaggi A. Immunocompetence of human microvascular brain endothelial cells: cytokine regulation oflL-lbeta, MCP-1, IL-10, sICAM-1 andsVCAM-1. J Neurol, 1998, V.245 № 11, P.727−30.
121. Li Q.Q., Bever C.T. Thl cytokines stimulate RANTES chemokine secretion by human astroglial cells depending on de novo transcription. Neuroehem Res, 2001, V.26 № 2, P.125−33.
122. Subileau E.A., Rezaie P., Davies H.A., Colyer F.M., Greenwood J., Male D.K., Romero I.A. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J Neuropathol Exp Neurol, 2009, V.68 № 3, P.227−40.
123. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med, 1990, V.172 № 4, P. 1193−200.
124. Seifart C., Plagens A., Dempfle A., Clostermann U., Vogelmeier C., von Wichert P., Seifart U. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers, 2005, V.2l№ 3, P. 157−65.
125. Romagnani S., The Thl/Th2 paradigm. Immunol Today, 1997, Том.18 N45, стр.263−6.
126. Гусев Е.И. Рассеянный склероз и другие демиелинизирующие заболевания. II Миклош. 2004.-540 с.
127. Zimonjic D.B., Rezanka L.J., Evans С.Н., Polymeropoulos M.H., Trent J.M., Popescu N.C. Mapping of the immune interferon gamma gene (IFNG) to chromosome band 12ql4 by fluorescence in situ hybridization. Cytogenet Cell Genet, 1995, V.7l№ 3, P.247−8.
128. Naylor S.L., Sakaguchi A.Y., Shows T.B., Law M.L., Goeddel D.V., Gray P.W. Human immune interferon gene is located on chromosome 12. J Exp Med, 1983, V.157 № 3, P. 1020−7.
129. Gray P.W., Goeddel D.V. Structure of the human immune interferon gene. Nature, 1982, Y.298 № 5877, P.859−63.
130. Awad M., Pravica V., Perrey C., El Gamel A., Yonan N., Sinnott P.J., Hutchinson I.V. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol, 1999, V.60№ 4, P.343−6.
131. Bream J.H., Carrington M., O’Toole S., Dean M., Gerrard В., Shin H.D., Kosack D" Modi W., Young H.A., Smith M.W. Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics, 2000, V.5l№l, P.50−8.
132. Brennan F.M., Mclnnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest, 2008, V.118 №l 1, P.3537−45.
133. Steinman L. Nuanced roles of cytokines in three major human brain disorders. J Clin Invest, 2008, V.118 № 11, P.3557−63.
134. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev, 2002, V.13 № 4−5, P.357−68.
135. El-Behi M., Rostami A., Ciric B. Current Views on the Roles ofThl and Thl7 Cells in Experimental Autoimmune Encephalomyelitis. J Neuroimmune Pharmacol, 2010, V.5 № 2, P. 189−97.
136. Eugster H.P., Frei K., Kopf M., Lassmann H., Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol, 1998, V.28№ 7, P.2178−87.
137. Riikola A., Sipila K., Kahonen M., Jula A., Nieminen M.S., Moilanen L., Kesaniemi Y.A., Lehtimaki T., Hulkkonen J. Interleukin-6 promoter polymorphism and cardiovascular risk factors: The Health 2000 Survey. Atherosclerosis, 2009, V.207 № 2, P.466−70.
138. Settin A., Zedan M., Farag M., Ezz El Regal M., Osman E. Gene polymorphisms of IL-6(-174) G/C and IL-IRa VNTR in asthmatic children. Indian J Pediatr, 2008, V.75 № 10, P.1019−23.
139. Chatenoud L. Protection from autoimmunity: immunological indifference versus T-cell mediated suppression? Eur J Immunol, 2006, V.36 № 9, P.2296−8.
140. Ring C.J., Cho K.W. Specificity in transforming growth factor-beta signaling pathways. Am J Hum Genet, 1999, Y.64 № 3, P.691−7.
141. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors, 2004, V.22N-4, P.233−41.
142. Kingsley D.M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev, 1994, V.8 N'2, P. 133−46.
143. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol, 1998, V.16, P. 137−61.
144. McCartney-Francis N.L., Frazier-Jessen M., Wahl S.M. TGF-beta: a balancing act. Int Rev Immunol, 1998, V.16 № 5−6, P.553−80.
145. Engel M.E., Datta P.K., Moses H.L. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J Cell Biochem Suppl, 1998, V.30−31, P. l 11−22.
146. Fontana A., Constam D.B., Frei K., Malipiero U., Pfister H.W. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol, 1992, V.99 N’l, P. 1−7.
147. Delvig A.A., Lee J.J., Chrzanowska-Lightowlers Z.M., Robinson J.H. TGF-betal and IFN-gamma cross-regulate antigen presentation to CD4 T cells by macrophages. J Leukoc Biol, 2002, V.72N-1, P.163−6.I
148. Solari V., Owen D., Puri P. Association of transforming growth factor-betal gene polymorphism with reflux nephropathy. J Urol, 2005, V.174 № 4 Pt 2, P.1609−11- discussion 1611.
149. Yamada Y., Fujisawa M., Ando F., Niino N., Tanaka M., Shimokata H. Association of a polymorphism of the transforming growth factor-betal gene with blood pressure in Japanese individuals. J Hum Genet, 2002, V.47 № 5, P.243−8.
150. Shapira L., van Dyke T.E., Hart T.C. A localized absence of interleukin-4 triggers periodontal disease activity: a novel hypothesis. Med Hypotheses, 1992, V.39 № 4, P.319−22.
151. Mangan D.F., Robertson B., Wahl S.M. IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes. J Immunol, 1992, V.148 № 6, P.1812−6.
152. Hunt P.J., Marshall S.E., Weetman A.P., Bell J.I., Wass J.A., Welsh K.I. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab, 2000, Y.85 № 5, P. 1984−8.
153. Rosenwasser L.J., Klemm DJ., Dresback J.K., Inamura H., Mascali J.J., Klinnert M., Borish L. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy, 1995, V.25 Suppl 2, P.74−8- discussion 95−6.
154. Rosenwasser L.J., Borish L. Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med, 1997, V.156№ 4Pt2, P. S152−5.
155. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med, 1998, V.338 № 7, P.436−45.
156. Baggiolini M. Chemokines and leukocyte traffic. Nature, 1998, V.392 № 6676, P.565−8.216. dos Santos A.C. Barsante M.M., Arantes R.M., Bernard C.C., Teixeira M.M., Carvalhot
157. Tavares J., CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis—an intravital microscopy study. J Neuroimmunol, 2005, V.162 № 1−2, P. 122−9.
158. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol, 1998, V.84№ 2, P.238−49.
159. Simpson J., Rezaie P., Newcombe J., Cuzner M.L., Male D., Woodroofe M.N. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol, 2000, V.108 № 1−2, P.192−200.
160. Lee C., Liu Q.H., Tomkowicz B., Yi Y., Freedman B.D., Collman R.G. Macrophage activation through CCR5- and CXCR4-mediated gpl20-elicited signaling pathways. J Leukoc Biol, 2003, V.74№ 5, P.676−82.
161. Kabelitz D., Wesch D., Features and functions of gamma delta T lymphocytes: focus on chemokines and their receptors. Crit Rev Immunol, 2003, V.23 № 5−6, P.339−70.
162. Menten P., Wuyts A., Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev, 2002, V.13 № 6, P.455−81.
163. Raport C.J., Gosling J., Schweickart V.L., Gray P.W., Charo I.F. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-lbeta, andMIP-1 alpha. J Biol Chem, 1996, V.271 № 29, P.17 161−6.
164. Samson M., Labbe O., Mollereau C., Vassart G., Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry, 1996, V.35 № 11, P.3362−7.
165. Calabresi P.A., Martin R., Jacobson S. Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. J Neurovirol, 1999, V.5 № 1, P. 102−8.
166. Garred P., Madsen H.O., Petersen J., Marquart H., Hansen T.M., Freiesleben Sorensen S., Volck B., Svejgaard A., Andersen V. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol, 1998, V.25№ 8, P.1462−5.
167. Ram M., Sherer Y., Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol, 2006, V.26№ 4, P.299−307.
168. Proost P., Van Damme J., Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun, 1993, V.192 № 3, P. 1175−81.
169. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol, 1995, V.154 № 9, P.4379−89.
170. Nelissen I., Vandenbroeck K., Fiten P., Hillert J., Olsson T., Marrosu M.G., Opdenakker G. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol, 2000, V.105 №l, P.58−63.
171. Nelissen I., Dubois B., Goris A., Ronsse I., Carton H., Opdenakker G. Gelatinase B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis. J Neurol Sci, 2002, V.200 N'1−2, P.43−8.
172. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 2001, V.17, P.463−516.
173. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol, 1997, V.74 № 2, P. l 11−22.
174. Lacraz S., Nicod L.P., Chicheportiche R., Welgus H.G., Dayer J.M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest, 1995, V.96 № 5, P.2304−10.
175. Gardner J., Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-l: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res, 2003, V.74 № 6, P.801−6.
176. Avolio C., Ruggieri M., Giuliani F., Liuzzi G.M., Leante R., Riccio P., Livrea P., Trojano M. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol, 2003, V.136N-1−2, P.46−53.
177. Waubant E., Goodkin D., Bostrom A., Bacchetti P., Hietpas J., Lindberg R., Leppert D. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology, 2003, V.60 №l, P.52−7.
178. Brown C.J., Flenniken A.M., Williams B.R., Willard H.F. X chromosome inactivation of the human TIMP gene. Nucleic Acids Res, 1990, V.18N-14, P.4191−5.
179. Wang X., Tromp G., Cole C.W., Verloes A., Sakalihasan N., Yoon S., Kuivaniemi H. Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and 2 (TIMP2) in patients with aneurysms. Matrix Biol, 1999, V.18 № 2, P. 121−4.
180. Svejgaard A., Ryder L.P. HLA and disease associations: detecting the strongest association. Tissue Antigens, 1994, V.43N'l, P. 18−27.
181. Compston D.A., Kellar Wood H., Robertson N., Sawcer S., Wood N.W. Genes and susceptibility to multiple sclerosis. Acta Neurol Scand Suppl, 1995, V.161, P.43−51.
182. Chistyakov D.A., Savost’anov K.V., Turakulov R.I., Petunina N.A., Trukhina L.V., Kudinova A.V., Balabolkin M.I., Nosikov V.V. Complex association analysis of graves disease using a set of polymorphic markers. Mol Genet Metab, 2000, V.70 № 3, P.214−8.
183. Rasmussen H.B., Kelly M.A., Francis D.A., Clausen J. CTLA4 in multiple sclerosis. Lack of genetic association in a European Caucasian population but evidence of interaction with HLA-DR2 among Shanghai Chinese. J Neurol Sci, 2001, V.184 № 2, P.143−7.
184. Harbo H.F., Celius E.G., Vartdal F., Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens, 1999, V.53N'l, P.106−10.
185. Ligers A., Xu C., Saarinen S., Hillert J., Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol, 1999, V.97 № 1−2, P. 182−90.
186. Hradsky O., Dusatkova P., Lenicek M., Bronsky J., Nevoral J., Vitek L., Lukas M., Zeniskova I., Cinek O. The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn’s disease. BMC Med Genet, 2010, V. ll, P.91.
187. Fukazawa T., Yanagawa T., Kikuchi S., Yabe I., Sasaki H., Hamada T., Miyasaka K., Gomi K., Tashiro K. CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J Neurol Sci, 1999, V.171 №l, P.49−55.
188. Pertovaara M., Antonen J., Hurme M. Th2 cytokine genotypes are associated with a milder form ofprimary Sjogren’s syndrome. Ann Rheum Dis, 2006, V.65 N'5, P.666−70.
189. Izad M., Vodjgani M., Nicknam M.H., Lotfi J., Fathi D., Amirzargar A.A. Interferon-gamma gene polymorphism in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol, 2004, V.3 № 3, P. 115−9.
190. Shawkatova I., Javor J., Parnicka Z., Vrazda L., Novak M., Buc M. No association between cytokine gene polymorphism and risk of Alzheimer’s disease in Slovaks. Acta Neurobiol Exp (Wars), 2010, V.70№ 3, P.303−7.
191. Holla L.I., Fassmann A., Stejskalova A., Znojil V., Vanek J., Vacha J. Analysis of the interleukin-6 gene promoter polymorphisms in Czech patients with chronic, periodontitis. J Periodontal, 2004, V.75№l, P.30−6.
192. Tervonen Т., Raunio Т., Knuuttila M., Karttunen R. Polymorphisms in the CD14 and IL-6 genes associated with periodontal disease. J Clin Periodontol, 2007, V.34 № 5, P.377−83.
193. Brett P.M., Zygogianni P., Griffiths G.S., Tomaz M., Parkar M., D’Aiuto F., Tonetti M. Functional gene polymorphisms in aggressive and chronic periodontitis. J Dent Res, 2005, V.84 № 12, P. l 149−53.
194. Nibali L., D’Aiuto F., Donos N., Griffiths G.S., Parkar M., Tonetti M.S., Humphries S.E., Brett P.M. Association between periodontitis and common variants in the promoter of the interleukin-6gene. Cytokine, 2009, V.45№l, P.50−4.
195. Favorova O.O., Favorov A.V., Boiko A.N., Andreewski T.V., Sudomoina M.A., Alekseenkov A.D., Kulakova O.G., Gusev E.I., Parmigiani G., Ochs M.F. Three allele combinations associated with multiple sclerosis. BMC Med Genet, 2006, V.7, P.63.
196. Коненков B.H.j Голованова O.B., Дортман B.B., Шевченко A.B., Карпова А. В. Полиморфизм гена TNFA и неравновесное сцепление TNFA и HLA-генов II класса (DRB1, DQA1 DQB1) в популяции сибирских европеоидов Иммунология, 2008, Том 29 № 1, стр.6−10.
197. Mycko M., Kowalski W., Kwinkowski M., Buenafe A.C., Szymanska В., Tronczynska E., Plucienniczak A., Selmaj K. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol, 1998, V.84 № 2, P. 198 206.
198. Klein W., Tromm A., Griga Т., Fricke H.', Folwaczny С., Носке M., Eitner K., Marx M., Duerig N., Epplen J.T. Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases. Genes Immun, 2001, V.2 № 5, P.287−9.
199. Heward J.M., Nithiyananthan R., Allahabadia A., Gibson S., Franklyn J. A-, Gough S.C. No association of an interleukin 4 gene promoter polymorphism with Graves' disease in the United Kingdom. J Clin Endocrinol Metab, 2001, V.86 № 8, P.3861−3.
200. Amirzargar A.A., Movahedi M., Rezaei N., Moradi В., Dorkhosh S., Mahloji M., Mahdaviani S.A. Polymorphisms in IL4 and iLARA confer susceptibility to asthma. J Investig Allergol Clin Immunol, 2009, V.19№ 6, P.433−8.
201. Gervaziev Y.V., Kaznacheev V.A., Gervazieva V.B. Allelic polymorphisms in the interleukin-4 promoter regions and their association with bronchial asthma among the Russian population. Int Arch Allergy Immunol, 2006, V.141 N'3, P.257−64.
202. Bennetts В.Н., Teutsch S.M., Buhler М.М., Heard R.N., Stewart G.J. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol, 1997, V.58 №l, P.52−9.
203. Saenz-Lopez P., Carretero R., Cozar J.M., Romero J.M., Canton J., Vilchez J.R., Tallada M., Garrido F., Ruiz-Cabello F. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, V.8, P.382.
204. Ahad M.A., Missotten Т., Abdallah A., Lympany P.A., Lightman S. Polymorphisms of chemokine and chemokine receptor genes in idiopathic immune-mediated posterior segment uveitis. Mol Vis, 2007, V.13, P.388−96.
205. Yao T.C., Tsai Y.C., Huang J.L. Association of RANTES promoter polymorphism with juvenile rheumatoid arthritis. Arthritis Rheum, 2009, V.60 N'4, P.1173−8.
206. Hulkkonen J., Pertovaara M., Antonen J., Pasternack A., Hurme M., Pollanen P., Lehtimaki T. Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren’s syndrome. Rheumatology (Oxford), 2004, V.43 № 12, P. 1476−9.
207. Yi Y.C., Chen M.K., Chen L.Y., Ho E.S., Ying JT.H., Wang P.H., Yang S.F. Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer. Clin Chim Acta, 2009, V.409 №l-2, P. 127−31.
208. Фаворова O.O., Кулакова О. Г., Бойко A.H., Рассеянный склероз как полигенное заболевание: современное состояние проблемы. Генетика, 2010, Том 46 № 3, стр.302−313.
209. Risch N., Teng J. The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases I. DNA pooling. Genome Res, 1998, V.8 № 12, P.1273−88.
210. Haldar Т., Ghosh S. Power comparison between population-based case-control studies and family-based transmission-disequilibrium tests: An empirical study. Indian J Hum Genet, 2011, V.17 Suppl 1, P. S27−31.
211. Kamali-Sarvestani Е., Nikseresht A., Aflaki Е., Sarvari J., Gharesi-Fard В. TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol Scand, 2007, V.115N-3, P.161−6.
212. Dong Y.X., Xu Z.R., Lin P.Y. Association among serous and cerebrospinal fluid TNF-alpha level, gene polymorphisms of TNF-alpha and multiple sclerosis in Han nationality of southern China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2006, V.23 № 6, P.677−9.
213. Mihailova S., Ivanova M., Mihaylova A., Quin L., Mikova O., Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. JNeuroimmunol, 2005, V.168№l-2, P.138−43.
214. Malferrari G., Stella A., Monferini E., Saltini G., Proverbio M.C., Grimaldi L.M., Rossi-Bernardi L., Biunno I. Ctla4 and multiple sclerosis in the Italian population. Exp Mol Pathol, 2005, V.78N-1, P.55−7.
215. Akkad D.A., Arning L., Ibrahim S.M., Epplen J.T. Sex specifically associated promoter polymorphism in multiple sclerosis affects interleukin 4 expression levels. Genes Immun, 2007, V.8 № 8, P.703−6.
216. Urcelay E., Santiago J.L., Mas A., Martinez A., de Las Heras V., Arroyo R., de la Concha E.G. Role of interleukin 4 in Spanish multiple sclerosis patients. J Neuroimmunol, 2005, V.168N'l-2, P.164−7.
217. Silversides J.A., Heggarty S.V., McDonnell G.V., Hawkins S.A., Graham C.A. Influenceof CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. i
218. Mult Scler, 2004, V.10N-2, P.149−52.
219. Pulkkinen K., Luomala M., Kuusisto H., Lehtimaki T., Saarela M., Jalonen T.O., Elovaara I. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand, 2004, V.109N-5, P.342−7.